Safety and efficacy of everolimus with exemestane vs. Exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2

• Main Authors: Kathleen I. Pritchard, Howard A. Burris, Yoshinori Ito, Hope S. Rugo, Shaker Dakhil, Gabriel N. Hortobagyi, Mario Campone, Tibor Csöszi, José Baselga, Puttisak Puttawibul, Martine Piccart, Daniel Heng, Shinzaburo Noguchi, Vichien Srimuninnimit, Hugues Bourgeois, Antonio Gonzalez Martin, Karen Osborne, Ashok Panneerselvam, Tetiana Taran, Tarek Sahmoud, Michael Gnant
• Other Authors: University of Toronto
• Format: Article
• Published: 2018
• Subjects: Biochemistry, Genetics and Molecular Biology; Medicine
• Online Access: https://repository.li.mahidol.ac.th/handle/123456789/31429
• Institution: Mahidol University

Background Postmenopausal women with hormone receptor-positive (HR+) breast cancer in whom disease progresses or there is recurrence while taking a nonsteroidal aromatase inhibitor (NSAI) are usually treated with exemestane (EXE), but no single standard of care exists in this setting. The BOLERO-2 t...